Ernexa shareholders OK 2026 equity incentive plan
Ernexa Therapeutics Inc. reported the results of its 2026 Annual Meeting of Stockholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Ernexa Therapeutics Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the May 6, 2026 record date, there were 1,166,333 common shares outstanding, and 619,741 shares, or about 53.13%, were represented, establishing a quorum.
Stockholders elected five directors to serve until the 2027 annual meeting, ratified Haskell & White LLP as independent auditor for the 2026 fiscal year, and approved the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan. No other matters were brought to a vote.
8-K Event Classification
2 items: 5.07, 9.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Shares outstanding on record date: 1,166,333 shares
Shares represented at meeting: 619,741 shares
Quorum percentage: 53.13%
+4 more
7 metrics
Shares outstanding on record date
1,166,333 shares
Common stock outstanding as of May 6, 2026 record date
Shares represented at meeting
619,741 shares
Common shares present or by proxy at 2026 Annual Meeting
Quorum percentage
53.13%
Portion of outstanding shares represented at Annual Meeting
Votes for auditor ratification
590,236 votes
For Haskell & White LLP as 2026 independent auditor
Votes for equity incentive plan
363,640 votes
For 2026 Omnibus Equity Incentive Plan
Votes against equity incentive plan
94,840 votes
Against 2026 Omnibus Equity Incentive Plan
Director support example
455,633 votes
Votes for director nominee Elena Ratner
Key Terms
record date, quorum, broker non-votes, independent registered public accounting firm, +1 more
5 terms
record date financial
"As of the close of business on May 6, 2026, the record date for the Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
quorum financial
"619,741 shares ... were represented in person or by proxy at the Annual Meeting, constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes financial
"Votes | Votes | Broker Director | For | Withheld | Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Omnibus Equity Incentive Plan financial
"The Company’s stockholders approved the adoption of the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan"
A single, company-wide plan that lets a business grant different kinds of stock-based pay — such as stock options, shares that vest over time, or other equity awards — to employees, directors and consultants. It matters to investors because it determines how much of the company can be paid out in shares, how quickly those shares enter the market, and how well employees are motivated to grow the business; think of it as a toolbox or menu for paying with ownership stakes that can dilute existing holders and affect company performance.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ernexa Therapeutics (ERNA) stockholders approve at the 2026 Annual Meeting?
Ernexa Therapeutics stockholders approved three key items. They elected five directors, ratified Haskell & White LLP as the independent auditor for the 2026 fiscal year, and approved the 2026 Omnibus Equity Incentive Plan, which governs future stock-based compensation awards.
Were Ernexa Therapeutics (ERNA) director nominees elected at the 2026 Annual Meeting?
All five Ernexa director nominees were elected. James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, and William Wexler each received between 442,564 and 455,633 votes “For,” with relatively few votes withheld and broker non-votes reported for each nominee.
Which auditor did Ernexa Therapeutics (ERNA) stockholders ratify for the 2026 fiscal year?
Stockholders ratified Haskell & White LLP as auditor. The ratification received 590,236 votes “For,” 29,010 votes “Against,” and 495 abstentions. There were no broker non-votes on this proposal, confirming broad support for retaining the existing independent registered public accounting firm.
Did Ernexa Therapeutics (ERNA) approve the 2026 Omnibus Equity Incentive Plan?
Yes, stockholders approved the 2026 Omnibus Equity Incentive Plan. The plan received 363,640 votes “For,” 94,840 votes “Against,” 96 abstentions, and 161,165 broker non-votes. This approval allows the company to grant future equity-based awards under the new plan framework.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates